The underlying mechanism relates to body fats role in estrogen production
In the Phase 2 trial published in the New England Journal of Medicine (2023), retatrutide was administered as a once-weekly subcutaneous injection using a structured dose-escalation schedule
When you superimpose patients with obesity but with low muscle mass and strength, they are at greater risk of adverse outcomes, Batsis says
Conversely, in a randomized controlled trial involving adults with T2DM, administration of liraglutide for 26 weeks in addition to standard therapy with insulin, although significantly decreased body weight and levels of glycated hemoglobin HbA1c in patients, but at the same time failed to reduce Becks Depression Inventory (BDI) scores (de Witt 2014)
[76] found no evidence of increased risk of suicidal ideation and self-injury associated with GLP-1 RAs compared to SGLT-2 inhibitors in individuals with T2DM and obesity, based on data from the Valencia Health System Integrated Database (VID) (per-protocol analysis: HR, 1.04
Other Weight Loss Medications Various pharmaceutical options for appetite suppression or metabolism support
